DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR LEVOMILNACIPRAN HYDROCHLORIDE
Clinical Trials for Levomilnacipran Hydrochloride
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00969150 | Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder | Completed | Forest Laboratories | Phase 3 | The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder. |
NCT00969709 | Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder | Completed | Forest Laboratories | Phase 3 | The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder. |
NCT01034462 | Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder | Completed | Forest Laboratories | Phase 3 | The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder |
NCT01254305 | Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder | Completed | Forest Laboratories | Phase 2 | The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD). |
NCT01377194 | Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder | Completed | Forest Laboratories | Phase 3 | The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD). |
NCT02265367 | Novel Medication as a Potential Smoking Cessation Aid | Recruiting | University of Minnesota - Clinical and Translational Science Institute | N/A | The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates. |
NCT02288325 | A Multicenter, Relapse Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder | Active, not recruiting | Forest Laboratories | Phase 4 | This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse (MDD). |
Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Levomilnacipran Hydrochloride
Clinical Trial Locations for Levomilnacipran Hydrochloride
Trials by Country
Clinical Trial Progress for Levomilnacipran Hydrochloride
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Levomilnacipran Hydrochloride
Sponsor Name